Bg Medicine (BGMD) 0.1646 $BGMD BG Medicine Wit
Post# of 273257
Posted On: 09/04/2016 7:15:54 AM
Bg Medicine (BGMD) 0.1646 $BGMD
BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3(R) Test
GlobeNewswire - Wed Dec 23, 6:50AM CST
BG Medicine, Inc. (OTCQB:BGMD) today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration ("FDA"
that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3(R) Test for a potential new indication for use as an aid in the assessment of the near-term risk of fatal cardiovascular events in older adults who have no prior history of cardiovascular disease, cerebrovascular disease or vascular disease.
License and Distribution Agreement Amended
GlobeNewswire - Mon Nov 30, 6:39AM CST
BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3 Test, today announced an amendment to its license and distribution agreement for Galectin-3.
BG Medicine Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 17, 6:50AM CST
BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3 Test, today reported financial results for the three and nine months ended September 30, 2015.
BG Medicine Announces Business Update Conference Call Information
GlobeNewswire - Wed Nov 11, 3:30PM CST
BG Medicine, Inc. (OTCQB:BGMD) today announced that the company will host a business update conference call and webcast on Tuesday, November 17, 2015, beginning at 8:30 a.m. Eastern Time.
BG Medicine Due Diligence Report: Quietly Making Headway - Broad Street Alerts
ACCESSWIRE - Thu Nov 05, 7:33AM CST
NEW YORK, NY / ACCESSWIRE / November 5, 2015 / BG Medicine, Inc. (OTCQB: BGMD) the developer of the BGM Galectin-3 recently announced that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on Wednesday, September 16, 2015, due to the Company's continuing non-compliance with the stockholders' equity requirement set forth in NASDAQ Listing Rule 5550(b) as of September 10, 2015. The September 10, 2015 date constituted the outside date by which the Company must remedy the listing deficiency in accordance with the discretion afforded the NASDAQ Listing Qualifications Hearings Panel under the NASDAQ Listing Rules. The Company understands that its common stock will be formally delisted from NASDAQ via NASDAQ's filing of a Form 25 "Notification of Delisting" with the Securities Exchange Commission after all applicable review and appeal periods have lapsed. The Company's common stock began trading on the OTC Market's OTCQB market tier effective with the open of business on September 16, 2015.
Analysis of the United States Cardiac Biomarker Diagnostics Market
M2 - Wed Oct 14, 6:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2hrjds/analysis_of_the) has announced the addition of the "Analysis of the Cardiac Biomarker Diagnostics Market" report to their offering. The cardiac biomarker diagnostics market is a niche but upcoming space in the United States. With regulations favoring personalized medicine and diagnostics, large companies are focusing their investment in researching and detecting new biomarkers to differentiate their products in this competitive market. In addition to growing prevalence rates that are driving this market, the increasing use of point-of-care testing devices at ambulatory and at clinical settings spurs this market in the region. The push towards a more patient centric and wholesome care places imaging companies that can provide a more comprehensive diagnostic product are at an advantage in this market. Key Findings: - There is an increasing number of publications discussing the importance of point-of-care tests (POCT) in improving patient outcomes. This is spurring adoption rate at a clinical and ambulatory level - With the implementation of Affordable Care Act (ACA), there is a shift toward value-based care. This is increasing pressure on manufacturers to produce more cost efficient and efficient devices for consumers, especially in the hospital sector - Manufacturers are seeing the value of integrated and wholesome platform solutions in this emerging value-based system Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Competitive Playbook 4. Emerging Biomarkers 5. Driver and Restraints-Total Cardiac Biomarker Diagnostics Market 6. Forecasts and Trends-Total Cardiac Biomarker Diagnostics Market 7. Competitive Environment 8. POCT Segment Analysis 9. Lab-based Segment Analysis 10. The Full Picture-Cardiac Diagnostics Industry Overview 11. Cardiac Imaging Diagnostics 12. ECG in Cardiac Diagnostics 13. Opportunities 14. The Last Word 15. Appendix Companies Mentioned - Abbott - Beckman Coulter - BG Medicine - Boditech Diagnostics - Diadexus - Fisher Diagnostics - Fujirebio Diagnostics - Roche - Siemens - ThermoFisher For more information visit http://www.researchandmarkets.com/research/2h...sis_of_the
Global Diagnostics Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts for 150+ Companies
M2 - Tue Sep 22, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm3w3j/global) has announced the addition of the "Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering. The Global Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: - Companion Diagnostics - Imaging - CT - Endoscope - Molecular and nuclear - MRI - Ultrasound - X-ray - PET - SPECT - Angiography - Fluroscopy - Mammography - In vitro diagnostics - Molecular diagnostics - Prognostics - Theranostics Report scope: Global Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide. Global Diagnostics Partnering 2010-2015 includes: - Trends in diagnostic dealmaking in the biopharma industry since 2010 - Analysis of diagnostic deal structure - Case studies of real-life diagnostic deals - Access to over 3,000 diagnostic deals - The leading diagnostic deals by value since 2010 - Most active diagnostic dealmakers since 2010 - The leading diagnostic partnering resources In Global Diagnostics Partnering 2010-2015 , the available contracts are listed by: - Headline value - Stage of development at signing - Deal component type - Specific therapy target Companies Mentioned - Partial List - Abaxis - Abbott Laboratories - Accuray - Achaogen - Actavis (acquired by Watson) - Acusphere - ADMA Biologics - Aegea Biotechnologies - Alnylam Pharmaceuticals - Alseres Pharmaceuticals - Altair Nanotechnologies - Amarantus BioSciences - Ambit Biosciences - AMDL Diagnostics - AmpliPhi Biosciences - Amway Global - ARK Diagnostics - Arno Therapeutics - Arrayit - Arrayit Diagnostics - AspenBio Pharma - Asuragen - Atossa Genetics - Audeo Oncology - Axial Biotech - Bayer Schering Pharma - Beckman Coulter - Beijing C&D - BG Medicine - Bio-Imaging Technologies - Bio-Matrix Scientific - Biocept - BioClinica - Biofield - Biogen Idec For more information visit http://www.researchandmarkets.com/research/hm3w3j/global
BIIB: 313.59 (+7.56), ABT: 42.09 (-0.21), ADMA: 5.79 (+0.02), APPY: 3.76 (-0.10), APHB: 1.60 (+0.01), ATOS: 2.42 (+0.01), ABAX: 49.50 (-0.90)
BG Medicine to begin trading on the OTCQB under current trading symbol BGMD
M2 - Wed Sep 16, 5:45AM CDT
Diagnostic solutions company BG Medicine (NasdaqCM:BGMD) stated on Tuesday that the trading of its common stock will be suspended on NASDAQ effective with the open of business on 16 September 2015.
BG Medicine to Begin Trading on the OTCQB
GlobeNewswire - Tue Sep 15, 12:27PM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today announced that on September 14, 2015, the Company was notified by The NASDAQ Stock Market LLC ("NASDAQ" that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on Wednesday, September 16, 2015, due to the Company's continuing non-compliance with the stockholders' equity requirement set forth in NASDAQ Listing Rule 5550(b) as of September 10, 2015. The September 10, 2015 date constituted the outside date by which the Company must remedy the listing deficiency in accordance with the discretion afforded the NASDAQ Listing Qualifications Hearings Panel under the NASDAQ Listing Rules. The Company understands that its common stock will be formally delisted from NASDAQ via NASDAQ's filing of a Form 25 "Notification of Delisting" with the Securities Exchange Commission after all applicable review and appeal periods have lapsed.
Global Cardiac Markers Market 2015-2019 - Increased usage of POC diagnostic tests
M2 - Wed Sep 09, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dxnfg/global_cardiac) has announced the addition of the "Global Cardiac Markers Market 2015-2019" report to their offering. The global cardiac markers market to grow at a CAGR of 9.64% during 2014-2019. The report, Global Cardiac Markers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. POC diagnostic tests provide immediate results, which lead to instant treatment decisions. These tests are the preferred tools for diagnosis and are gaining popularity in patient treatment evaluation. Currently, the tests that are based on lateral flow immunoassays are also available for haemoglobin testing, pregnancy testing, food pathogen screening, faecal occult blood analysis, myocardial infraction, cholesterol testing, infectious disease testing, and blood glucose testing. POC tests act as a catalyst for the development of preventive medicine because of rapid tests results and a high level of accuracy. According to the report, hospitals and other healthcare centers are required to reduce healthcare spending without compromising the quality of treatment and by improving patient outcomes. This can be done with the early diagnosis of cardiac disorders, which allows physicians to take care of patients during the early stages, avoiding the need for hospital stays. Cardiac markers offer reliable and efficient disease diagnosis because of high-sensitivity test kits, short turnaround time, high productivity, and easy operation of instruments. This helps in maintaining quality and reducing the costs of healthcare services. Further, the report states lack of specific actions for detection of cardiac disorders is affecting the market growth. The various types of cardiac markers are: - Troponin test - Creatine Kinase test - Lactate dehydrogenase - Aspartate transaminase - Myoglobin - Ischemia-modified albumin - Pro-brain natriuretic peptide - Glycogen phosphorylase isoenzyme BB The other cardiac markers are C-reactive protein, homocysteine, pulmonary embolism (D-dimer test), and high-density and low-density lipoproteins. The report includes the present scenario and the growth prospects of the global cardiac markers market for 2015-2019. The market can be divided into the following segments: - By diagnosis facility: POC testing and laboratory testing - By assay type: Troponin I and BNP Key vendors - Abbott - Alere - Roche Diagnostics - Siemens Healthcare Other prominent vendors - AniBiotech - Axis-Shield - Beckman Coulter - Becton, Dickinson and Company - BG Medicine - Biomerieux - Boston Scientific - Critical Diagnostics - diaDexus - LifeSign - Mitsubishi Chemical Europe - Nanomix - Radiometer Medical - Randox Laboratories - Response Biomedical - Sierra Resources International - Singulex - Thermo Fisher Scientific - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/5d...al_cardiac
BSX: 24.26 (-0.07), TRIB: 13.36 (-0.05)
BG Medicine Provides Business Update and Reports Second Quarter 2015 Financial Results
GlobeNewswire - Fri Aug 14, 3:43PM CDT
Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S.
BG Medicine prices public offering of Series A units and Series B units
M2 - Fri Aug 14, 5:57AM CDT
Diagnostic solutions company BG Medicine (NasdaqCM:BGMD) announced on Thursday that it has priced its underwritten public offering of 2,315,654 Series A units.
BG Medicine Prices Underwritten Public Offering
GlobeNewswire - Thu Aug 13, 7:35AM CDT
(NASDAQ:BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3Test, today announced the pricing of an underwritten public offering of its equity securities. Roth Capital Partners is acting as sole manager for the offering.
BG Medicine to launch public offering of Series A units and Series B units
M2 - Thu Aug 13, 5:47AM CDT
Diagnostic solution company BG Medicine (NasdaqCM:BGMD) reported on Wednesday that it intends to issue Series A units of common stock and warrants in an underwritten public offering.
BG Medicine Announces Proposed Underwritten Public Offering
GlobeNewswire - Wed Aug 12, 3:29PM CDT
(NASDAQ:BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BG Medicine Welcomes U.S. Market Introduction of Automated Galectin-3 Test at the 2015 American Association for Clinical Chemistry Annual Meeting
GlobeNewswire - Mon Jul 27, 7:00AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT automated immunoassay analyzer will be presented at the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting to be held in Atlanta, GA from July 26 to July 30, 2015.
Automated Galectin-3 Blood Test Launch - Report on BG Medicine
PR Newswire - Tue Jul 21, 8:25AM CDT
ACI Association has initiated research coverage on BG Medicine, Inc., (NASDAQ: BGMD). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
BG Medicine announces final USD10m secured term loan payment
M2 - Thu Jul 16, 6:16AM CDT
BG Medicine (NasdaqCM:BGMD) declared on Wednesday the payoff of its USD10m secured term loan facility with General Electric Capital Corporation and Comerica Bank.
BG Medicine Announces One-for-Four Reverse Stock Split
GlobeNewswire - Wed Jul 08, 4:00PM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company's common stock will open for trading on the NASDAQ Capital Market on July 9, 2015 on a post-split basis.
BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3(R) Test
GlobeNewswire - Wed Dec 23, 6:50AM CST
BG Medicine, Inc. (OTCQB:BGMD) today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration ("FDA"
that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3(R) Test for a potential new indication for use as an aid in the assessment of the near-term risk of fatal cardiovascular events in older adults who have no prior history of cardiovascular disease, cerebrovascular disease or vascular disease. License and Distribution Agreement Amended
GlobeNewswire - Mon Nov 30, 6:39AM CST
BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3 Test, today announced an amendment to its license and distribution agreement for Galectin-3.
BG Medicine Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 17, 6:50AM CST
BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3 Test, today reported financial results for the three and nine months ended September 30, 2015.
BG Medicine Announces Business Update Conference Call Information
GlobeNewswire - Wed Nov 11, 3:30PM CST
BG Medicine, Inc. (OTCQB:BGMD) today announced that the company will host a business update conference call and webcast on Tuesday, November 17, 2015, beginning at 8:30 a.m. Eastern Time.
BG Medicine Due Diligence Report: Quietly Making Headway - Broad Street Alerts
ACCESSWIRE - Thu Nov 05, 7:33AM CST
NEW YORK, NY / ACCESSWIRE / November 5, 2015 / BG Medicine, Inc. (OTCQB: BGMD) the developer of the BGM Galectin-3 recently announced that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on Wednesday, September 16, 2015, due to the Company's continuing non-compliance with the stockholders' equity requirement set forth in NASDAQ Listing Rule 5550(b) as of September 10, 2015. The September 10, 2015 date constituted the outside date by which the Company must remedy the listing deficiency in accordance with the discretion afforded the NASDAQ Listing Qualifications Hearings Panel under the NASDAQ Listing Rules. The Company understands that its common stock will be formally delisted from NASDAQ via NASDAQ's filing of a Form 25 "Notification of Delisting" with the Securities Exchange Commission after all applicable review and appeal periods have lapsed. The Company's common stock began trading on the OTC Market's OTCQB market tier effective with the open of business on September 16, 2015.
Analysis of the United States Cardiac Biomarker Diagnostics Market
M2 - Wed Oct 14, 6:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2hrjds/analysis_of_the) has announced the addition of the "Analysis of the Cardiac Biomarker Diagnostics Market" report to their offering. The cardiac biomarker diagnostics market is a niche but upcoming space in the United States. With regulations favoring personalized medicine and diagnostics, large companies are focusing their investment in researching and detecting new biomarkers to differentiate their products in this competitive market. In addition to growing prevalence rates that are driving this market, the increasing use of point-of-care testing devices at ambulatory and at clinical settings spurs this market in the region. The push towards a more patient centric and wholesome care places imaging companies that can provide a more comprehensive diagnostic product are at an advantage in this market. Key Findings: - There is an increasing number of publications discussing the importance of point-of-care tests (POCT) in improving patient outcomes. This is spurring adoption rate at a clinical and ambulatory level - With the implementation of Affordable Care Act (ACA), there is a shift toward value-based care. This is increasing pressure on manufacturers to produce more cost efficient and efficient devices for consumers, especially in the hospital sector - Manufacturers are seeing the value of integrated and wholesome platform solutions in this emerging value-based system Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Competitive Playbook 4. Emerging Biomarkers 5. Driver and Restraints-Total Cardiac Biomarker Diagnostics Market 6. Forecasts and Trends-Total Cardiac Biomarker Diagnostics Market 7. Competitive Environment 8. POCT Segment Analysis 9. Lab-based Segment Analysis 10. The Full Picture-Cardiac Diagnostics Industry Overview 11. Cardiac Imaging Diagnostics 12. ECG in Cardiac Diagnostics 13. Opportunities 14. The Last Word 15. Appendix Companies Mentioned - Abbott - Beckman Coulter - BG Medicine - Boditech Diagnostics - Diadexus - Fisher Diagnostics - Fujirebio Diagnostics - Roche - Siemens - ThermoFisher For more information visit http://www.researchandmarkets.com/research/2h...sis_of_the
Global Diagnostics Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts for 150+ Companies
M2 - Tue Sep 22, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm3w3j/global) has announced the addition of the "Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering. The Global Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: - Companion Diagnostics - Imaging - CT - Endoscope - Molecular and nuclear - MRI - Ultrasound - X-ray - PET - SPECT - Angiography - Fluroscopy - Mammography - In vitro diagnostics - Molecular diagnostics - Prognostics - Theranostics Report scope: Global Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide. Global Diagnostics Partnering 2010-2015 includes: - Trends in diagnostic dealmaking in the biopharma industry since 2010 - Analysis of diagnostic deal structure - Case studies of real-life diagnostic deals - Access to over 3,000 diagnostic deals - The leading diagnostic deals by value since 2010 - Most active diagnostic dealmakers since 2010 - The leading diagnostic partnering resources In Global Diagnostics Partnering 2010-2015 , the available contracts are listed by: - Headline value - Stage of development at signing - Deal component type - Specific therapy target Companies Mentioned - Partial List - Abaxis - Abbott Laboratories - Accuray - Achaogen - Actavis (acquired by Watson) - Acusphere - ADMA Biologics - Aegea Biotechnologies - Alnylam Pharmaceuticals - Alseres Pharmaceuticals - Altair Nanotechnologies - Amarantus BioSciences - Ambit Biosciences - AMDL Diagnostics - AmpliPhi Biosciences - Amway Global - ARK Diagnostics - Arno Therapeutics - Arrayit - Arrayit Diagnostics - AspenBio Pharma - Asuragen - Atossa Genetics - Audeo Oncology - Axial Biotech - Bayer Schering Pharma - Beckman Coulter - Beijing C&D - BG Medicine - Bio-Imaging Technologies - Bio-Matrix Scientific - Biocept - BioClinica - Biofield - Biogen Idec For more information visit http://www.researchandmarkets.com/research/hm3w3j/global
BIIB: 313.59 (+7.56), ABT: 42.09 (-0.21), ADMA: 5.79 (+0.02), APPY: 3.76 (-0.10), APHB: 1.60 (+0.01), ATOS: 2.42 (+0.01), ABAX: 49.50 (-0.90)
BG Medicine to begin trading on the OTCQB under current trading symbol BGMD
M2 - Wed Sep 16, 5:45AM CDT
Diagnostic solutions company BG Medicine (NasdaqCM:BGMD) stated on Tuesday that the trading of its common stock will be suspended on NASDAQ effective with the open of business on 16 September 2015.
BG Medicine to Begin Trading on the OTCQB
GlobeNewswire - Tue Sep 15, 12:27PM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today announced that on September 14, 2015, the Company was notified by The NASDAQ Stock Market LLC ("NASDAQ"
that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on Wednesday, September 16, 2015, due to the Company's continuing non-compliance with the stockholders' equity requirement set forth in NASDAQ Listing Rule 5550(b) as of September 10, 2015. The September 10, 2015 date constituted the outside date by which the Company must remedy the listing deficiency in accordance with the discretion afforded the NASDAQ Listing Qualifications Hearings Panel under the NASDAQ Listing Rules. The Company understands that its common stock will be formally delisted from NASDAQ via NASDAQ's filing of a Form 25 "Notification of Delisting" with the Securities Exchange Commission after all applicable review and appeal periods have lapsed. Global Cardiac Markers Market 2015-2019 - Increased usage of POC diagnostic tests
M2 - Wed Sep 09, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dxnfg/global_cardiac) has announced the addition of the "Global Cardiac Markers Market 2015-2019" report to their offering. The global cardiac markers market to grow at a CAGR of 9.64% during 2014-2019. The report, Global Cardiac Markers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. POC diagnostic tests provide immediate results, which lead to instant treatment decisions. These tests are the preferred tools for diagnosis and are gaining popularity in patient treatment evaluation. Currently, the tests that are based on lateral flow immunoassays are also available for haemoglobin testing, pregnancy testing, food pathogen screening, faecal occult blood analysis, myocardial infraction, cholesterol testing, infectious disease testing, and blood glucose testing. POC tests act as a catalyst for the development of preventive medicine because of rapid tests results and a high level of accuracy. According to the report, hospitals and other healthcare centers are required to reduce healthcare spending without compromising the quality of treatment and by improving patient outcomes. This can be done with the early diagnosis of cardiac disorders, which allows physicians to take care of patients during the early stages, avoiding the need for hospital stays. Cardiac markers offer reliable and efficient disease diagnosis because of high-sensitivity test kits, short turnaround time, high productivity, and easy operation of instruments. This helps in maintaining quality and reducing the costs of healthcare services. Further, the report states lack of specific actions for detection of cardiac disorders is affecting the market growth. The various types of cardiac markers are: - Troponin test - Creatine Kinase test - Lactate dehydrogenase - Aspartate transaminase - Myoglobin - Ischemia-modified albumin - Pro-brain natriuretic peptide - Glycogen phosphorylase isoenzyme BB The other cardiac markers are C-reactive protein, homocysteine, pulmonary embolism (D-dimer test), and high-density and low-density lipoproteins. The report includes the present scenario and the growth prospects of the global cardiac markers market for 2015-2019. The market can be divided into the following segments: - By diagnosis facility: POC testing and laboratory testing - By assay type: Troponin I and BNP Key vendors - Abbott - Alere - Roche Diagnostics - Siemens Healthcare Other prominent vendors - AniBiotech - Axis-Shield - Beckman Coulter - Becton, Dickinson and Company - BG Medicine - Biomerieux - Boston Scientific - Critical Diagnostics - diaDexus - LifeSign - Mitsubishi Chemical Europe - Nanomix - Radiometer Medical - Randox Laboratories - Response Biomedical - Sierra Resources International - Singulex - Thermo Fisher Scientific - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/5d...al_cardiac
BSX: 24.26 (-0.07), TRIB: 13.36 (-0.05)
BG Medicine Provides Business Update and Reports Second Quarter 2015 Financial Results
GlobeNewswire - Fri Aug 14, 3:43PM CDT
Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S.
BG Medicine prices public offering of Series A units and Series B units
M2 - Fri Aug 14, 5:57AM CDT
Diagnostic solutions company BG Medicine (NasdaqCM:BGMD) announced on Thursday that it has priced its underwritten public offering of 2,315,654 Series A units.
BG Medicine Prices Underwritten Public Offering
GlobeNewswire - Thu Aug 13, 7:35AM CDT
(NASDAQ:BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3Test, today announced the pricing of an underwritten public offering of its equity securities. Roth Capital Partners is acting as sole manager for the offering.
BG Medicine to launch public offering of Series A units and Series B units
M2 - Thu Aug 13, 5:47AM CDT
Diagnostic solution company BG Medicine (NasdaqCM:BGMD) reported on Wednesday that it intends to issue Series A units of common stock and warrants in an underwritten public offering.
BG Medicine Announces Proposed Underwritten Public Offering
GlobeNewswire - Wed Aug 12, 3:29PM CDT
(NASDAQ:BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BG Medicine Welcomes U.S. Market Introduction of Automated Galectin-3 Test at the 2015 American Association for Clinical Chemistry Annual Meeting
GlobeNewswire - Mon Jul 27, 7:00AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT automated immunoassay analyzer will be presented at the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting to be held in Atlanta, GA from July 26 to July 30, 2015.
Automated Galectin-3 Blood Test Launch - Report on BG Medicine
PR Newswire - Tue Jul 21, 8:25AM CDT
ACI Association has initiated research coverage on BG Medicine, Inc., (NASDAQ: BGMD). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
BG Medicine announces final USD10m secured term loan payment
M2 - Thu Jul 16, 6:16AM CDT
BG Medicine (NasdaqCM:BGMD) declared on Wednesday the payoff of its USD10m secured term loan facility with General Electric Capital Corporation and Comerica Bank.
BG Medicine Announces One-for-Four Reverse Stock Split
GlobeNewswire - Wed Jul 08, 4:00PM CDT
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company's common stock will open for trading on the NASDAQ Capital Market on July 9, 2015 on a post-split basis.
(0)
(0)Scroll down for more posts ▼